Acupuncture in Persistent Atrial Fibrillation

Sponsor
Kyunghee University Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02110537
Collaborator
Ministry of Health & Welfare, Korea (Other)
80
1
2
16
5

Study Details

Study Description

Brief Summary

The aim of this trial is to evaluate the effect of acupuncture on prevention of atrial fibrillation (AF) recurrence after electrical cardioversion (EC) for persistent AF patients resistant to the antiarrhythmic drugs (AADs).

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

This is a multicenter, prospective, participant and assessor blinded, randomized, sham-controlled clinical trial with 2 parallel arms. To evaluate the efficacy and safety of acupuncture, a total of 80 persistent AF participants will be recruited and randomly assigned to active acupuncture and sham acupuncture group. Both group commonly take antiarrhythmic medication during study period. These patients who are resistant to drug therapy will get a electrical cardioversion. After cardioversion, the recurrence rate and duration of atrial fibrillation free time will be evaluated.

This trial consists of 2 weeks of observation and medical therapy, 2 weeks of acupuncture intervention before EC, EC and acupuncture intervention, 7 weeks of additional intervention, and 5 weeks of follow-up. After randomization, participants receive 10 sessions of acupuncture treatments over 10 weeks. The outcome is assessed at 2, 4, 6, 8, and 16 week after randomization.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Trial to Evaluate the Antiarrhythmic Effects of Acupuncture for Drug Resistant Persistent Atrial Fibrillation: Randomized, Participant and Assessor Blinded, Sham-controlled, Clinical Trial
Study Start Date :
Mar 1, 2014
Anticipated Primary Completion Date :
Jul 1, 2015
Anticipated Study Completion Date :
Jul 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Acupuncture + flecainide

The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.

Procedure: Active Acupuncture
Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.

Drug: flecainide
Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
Other Names:
  • tambocor
  • Sham Comparator: Sham acupuncture + flecainide

    The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.

    Procedure: Sham acupuncture
    For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.

    Drug: flecainide
    Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
    Other Names:
  • tambocor
  • Outcome Measures

    Primary Outcome Measures

    1. Recurrence of atrial fibrillation evaluated on serial electrocardiography and 48 hour holter monitoring after sinus conversion by electrical cardioversion [3 months after electrical cardioversion]

      When patient feel symptoms such as palpitation and chest discomfort, the patients are recommended to visit hospital to check out the recurrence of atrial fibrillation.

    Secondary Outcome Measures

    1. Changes in function and volume of left atrium and left atrial appendage evaluated by echocardiography [3 months after electrical cardioversion]

    2. Change of inflammation marker (hsCRP) [3 months after electrical cardioversion]

      Other markers can be added

    3. Number of Participants with Adverse Events (AEs) [Participants will be followed for the duration of this study, an expected average 14 weeks]

      All participants and practitioners are taught to report any AEs. If there are any AEs, the following items are recorded by practitioners at each visit and appropriate actions are taken: type of AEs, occurrence date, lost date, frequency of occurrence, severity, causality with the treatment, actions taken with the acupuncture intervention, and actions taken to the participants. Serious AEs, i.e. death or life-threatening events which are required urgent intervention, will be noted to the principal investigators immediately and determine whether the participants are dropped out.

    4. the factor to make atrial fibrillation recur [3 months later after electrical cardioversion]

      we will perform multivariate regression analysis to know which factor makes atrial fibrillation recur irrespective of intervention method.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Persistent AF lasting ≥ 7 days

    • Ages in 20-75 years

    • Resistant with antiarrhythmic drugs

    • Written informed consent

    Exclusion Criteria:
    • Age below 20 years or above 75 years

    • Severe valvular heart disease

    • History of open heart surgery

    • History of treatment for myocardial infarction (MI) within recent 6 weeks

    • Patients under or requiring the administration of antiviral drugs

    • 2nd degree atrioventricular block or more than two fascicular block

    • Severe pulmonary, liver, or renal disease

    • Previous acupuncture treatment for cardiovascular condition within 3 months

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kyung Hee University Medical Center Seoul Dongdaemun-gu Korea, Republic of 130-701

    Sponsors and Collaborators

    • Kyunghee University Medical Center
    • Ministry of Health & Welfare, Korea

    Investigators

    • Principal Investigator: Weon Kim, Professor, Kyunghee University Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Weon Kim, Professor, Kyunghee University Medical Center
    ClinicalTrials.gov Identifier:
    NCT02110537
    Other Study ID Numbers:
    • HI13C0580
    First Posted:
    Apr 10, 2014
    Last Update Posted:
    Apr 10, 2014
    Last Verified:
    Apr 1, 2014
    Keywords provided by Weon Kim, Professor, Kyunghee University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 10, 2014